MedTrace Logo

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

NCT04514419 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2025-11-21

No results posted yet for this study

Summary

The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).

Conditions

Interventions

DRUG

HS627

Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).

DRUG

Pertuzumab

Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).

Sponsors & Collaborators

  • BioRay Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zefei Jiang, M.D · The Affiliated Hospital of Qingdao University

  • Haibo Wang, M.D · The Affiliated Hospital of Qingdao University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-28
Primary Completion
2024-09-11
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04514419 on ClinicalTrials.gov